UNSPSC 51385608: Methyl salicylate

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C8H8O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LAV5U5022Y, chemically known as 2-hydroxybenzoic acid, methyl ester but generally known as methyl salicylate, which bears US NIH Compound Identifier 4133. European Medicines Agency schedules Methyl salicylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14545MIG. Most nations schedule methyl salicylate under HS 29182300 and SITC 51393.

As of Q4 2014, METHYL SALICYLATE remains the US FDA Preferred Term for this commodity. Methyl salicylate bears US NLM identifiers UMLS ID C0066282 and NCI Concept Code C80564. SMILES: CC1=C(C(=C(C=C1)Cl)NC2=CC=CC=C2C(=O)O)Cl.

UNSPSC 51385608 Methyl salicylate (Commodity) represents a narrow chemical product category that state and local procurement activity shows is being procured primarily as a component within broader pharmaceutical and health-related purchasing initiatives rather than as a standalone commodity. The recent opportunities attributed to this code involve naloxone procurement, therapeutic pharmacy initiatives, and generic multi-source pharmaceutical supply agreements—none of which directly align with methyl salicylate's typical uses as a topical analgesic or rubefacient ingredient. The code appears to see limited direct purchasing activity under its nominal scope; issuing bodies are instead using it as a catch-all classification within larger pharmaceutical, health services, and cooperative purchasing frameworks administered by state health agencies, county health departments, and multi-state cooperative purchasing alliances.

Recent activity spans Florida, Texas, and Minnesota through different issuing structures. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 (noting the historical posting date inconsistency in source records). The Texas Health and Human Services Commission released RFI HHS0017013 on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription programs, reflecting state-level strategic sourcing rather than commodity-level procurement. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 with a March 26, 2026 response deadline for generic pharmaceuticals and OTC products, requiring NDC codes and cGMP certification with authorized wholesaler distribution through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC. The code shows minimal recent opportunities directly tied to methyl salicylate procurement; purchasing activity under this code is heavily influenced by federal compliance requirements (FDA, DSCSA, cGMP) and multi-jurisdictional cooperative purchasing frameworks rather than standalone state or local commodity buying.